Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

High-intensity Walking Rehabilitation in Outpatient Subacute Spinal Cord Injury

NCT07553923 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2026-05-26
Last updated
2026-06-29

Condition(s) studied

Spinal Cord Injuries (SCI)

Investigational drug(s) / intervention(s)

High-intensity RehabilitationUsual Care

High-intensity Rehabilitation: Participants will receive high-intensity physical therapy intervention

Usual Care: Usual care physical therapy

Study summary

People with incomplete spinal cord injury (SCI) often have some preserved movement and may regain walking ability, but recovery can be limited, and more effective rehabilitation approaches are needed.The goal of this clinical trial is to learn if high-intensity walking rehabilitation can improve walking recovery and overall neurological recovery in individuals with subacute SCI. The investigators are also exploring the process of incorporating this type of physical therapy approach in an outpatient rehabilitation setting.

The main questions it aims to answer are:

* Does high-intensity walking rehabilitation improve walking ability, compared to usual care for individuals with subacute spinal cord injury?
* What are some of the barriers and facilitators to delivering high-intensity walking rehabilitation in an outpatient setting?

The investigators will compare usual care rehabilitation to a high-intensity rehabilitation program to see if higher-intensity physical therapy leads to better walking outcomes and improved recovery. The study will also explore how feasible it is to deliver this type of program in a real-world outpatient rehabilitation setting and gather perspectives from both participants and clinicians.

Participants will:

* Attend regular outpatient physical therapy sessions focused on walking rehabilitation
* Receive either usual care or a higher-intensity walking program delivered by their physical therapist
* Have their activities, heart rate, step counts, and self-reported effort during therapy sessions monitored
* Complete walking, balance, and neurophysiological assessments at the start and end of rehabilitation
* Wear an activity monitor for one week at the beginning and end of the study to measure daily activity outside of therapy
* Participants who receive the higher-intensity intervention may participate in an interview to share their experiences with rehabilitation

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult (≥ 18 years of age) * Sustained a SCI within the past year * Motor incomplete SCI - classified as American Spinal Injury Association (ASIA) Impairment Scale levels C or D * Able to stand and initiate reciprocal steps through voluntary lower extremity movement but may require maximal physical assistance of at least one person and may include assistive devices (SWAT level 2A or above) * Indicate a walking-related goal on admission to outpatient physical therapy Exclusion Criteria: * Medical or movement restriction(s) that limit high-intensity standing or walking rehabilitation (e.g., weight bearing restriction to lower extremities, cardiovascular constraints) * Inability to understand or communicate verbally in English

Primary outcome measure(s)

  • Change from Baseline in the Ten Metre Walk Test — Baseline and end of rehabilitation (up to 12 weeks following baseline)
    Time to walk ten metres; lower times indicate faster walking speed

Trial sites (1)

FacilityCityRegionStatus
Glenrose Rehabilitation Hospital Edmonton Alberta Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07553923 on ClinicalTrials.gov ↗ ← All trials in Canada